在患有转移性割抵抗性前列腺癌的男性中,第一线治疗和预后组的生存率
Megan E V Caram1,2, Kyle Kumbier2, Phoebe A Tsao1,2
1Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Cancer medicine
|August 14, 2024
概括
预后实验室可以预测转移性割抵抗性前列腺癌 (mCRPC) 的存活率. 第一线治疗选择会影响疾病的进展,以及预后不佳的患者的整体存活率.
科学领域:
- 在瘤学瘤学.
- 前列腺癌研究 研究前列腺癌
- 临床结果 临床结果
背景情况:
- 转移性割抵抗性前列腺癌 (mCRPC) 呈现出不同的预后.
- 对于不同的患者前景,最佳的第一线治疗选择仍然不清楚.
研究的目的:
- 评估基线实验室值在预测mCRPC患者的生存结果中的有用性.
- 根据预后组评估一线治疗对生存的影响.
主要方法:
- 对4135名接受一线治疗的mCRPC患者进行了回顾性队列研究 (阿比拉,恩扎胺,多塞塔克塞尔,凯托可纳).
- 根据血红蛋白,白蛋白和性酸酶水平,患者被分为有利的,中间的或不良的预后组.
- 卡普兰-梅尔和多变量考克斯回归分析用于评估前列腺特异性抗原 (PSA) 无进展存活率 (PFS) 和整体存活率 (OS).
主要成果:
- 中位数PSA PFS为6.9个月,中位数OS为18.8个月.
- 根据预后组,生存时间因预后不同而有显著差异,预后不佳组的平均生存时间为5.7个月.
- 与abiraterone相比,使用基托可纳与预后不佳组的生存状况更差以及所有组的PSA PFS更差有关.
结论:
- 基线实验室值可以帮助预测mCRPC中的生存率和治疗反应.
- 第一线治疗选择影响所有mCRPC患者的疾病进展.
- 整体存活率受到治疗选择的影响,主要是治疗开始时预后不佳的患者.
相关概念视频
01:21Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
01:20Comparing the Survival Analysis of Two or More Groups
164
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
164
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:20Actuarial Approach
69
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
69
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K